Texas Settlement With Gilead Over Patient Support Services: What Manufacturers Need to Know

The Texas Attorney General’s office recently announced a $45 million settlement with Gilead Sciences, Inc.

On

The settlement resolves allegations that Gilead violated the Texas Health Care Program Fraud Prevention Act (THFPA) — the state-law analogous to the federal False Claims Act — and the Texas Anti-Kickback Statute (TAKS) in connection with the sale of 20 of the company’s human immunodeficiency virus (HIV) and hepatitis products.

The Gilead settlement comes only months after Texas’ nearly $34 million settlement with AstraZeneca Pharmaceuticals LP, which we previously discussed. Both cases rest on the same core theory: that free nurse and reimbursement support services gave prescribers expense relief by eliminating costs they otherwise would have incurred. 

The federal Anti-Kickback Statute and many state-law equivalents treat expense relief as a form of remuneration. In its 2003 compliance program guidance for pharmaceutical manufacturers, the US Department of Health and Human Services Office of Inspector General (OIG) warned that “if goods or services provided by the manufacturer eliminate an expense that the physician would have otherwise incurred … the arrangement may be problematic” when linked to federal health care program business. Taken together, the Gilead and AstraZeneca settlements show that Texas is actively applying the same theory under state law.

The Gilead Allegations

Like AstraZeneca, Gilead was alleged to have offered Texas providers improper incentives, including “free nurses” and reimbursement support services, to induce prescriptions paid for by Texas Medicaid, resulting in millions of dollars in tainted Medicaid claims. According to the Settlement Agreement and Release, Texas alleged that two programs constituted illegal remuneration under the THFPA and TAKS — the “Free Nurse Program” and the “Support Services Program.”

The settlement agreement names the two programs as the “Covered Conduct” but says little about how they worked. It describes the “Free Nurse Program” as “the offer and/or provision of free nursing services and education to prescribers and patients as in-kind remuneration” and the “Support Services Program” as “the assumption of reimbursement and administrative support services that prescribers are duty-bound to perform for their patients.” Gilead has denied, and continues to deny, both the allegations and the state’s “characterization or naming convention” of the programs, and the agreement is not an admission of liability. 

Nurse Educator Program (Texas’ “Free Nurse Program”)

The settlement does not tie the state’s program labels to Gilead’s program names, so the mapping below is our reading of Gilead’s public materials. Gilead’s Nurse Educator Program appears to be what Texas calls the “Free Nurse Program.”

A Support Path health care provider brochure describes the Nurse Educator Program. If a patient needs medication administration education, a Nurse Educator can “provide training to your patient in-person or virtually.” Patients enroll by calling the Support Path program line or by completing a Support Path enrollment form. The brochure says patients “should continue to contact [their provider] if they have any questions about their prescribed Gilead medication.” It also notes that Nurse Educators “cannot provide medical advice or in-office medication administration training.” 

Gilead’s Hepatitis Delta Nurse Educator Program webpage says the program offers “[a] Nurse Educator to support you as you get started on your journey” and “[i]n-person or virtual Nurse Educator support for injection training.” After enrollment, Nurse Educators may provide “[i]n-person or virtual medication administration training” and “[f]ollow-up calls to check in on how your injections are going.” The page also includes an FAQ asking “I have questions about my Hep Delta prescribed medication. Who should I call?” The answer reads: “Nurse Educators do not provide medical advice. Please contact your healthcare provider if you have questions about your Hep Delta prescribed medication or general medical questions.” The bottom of the page repeats the disclaimer that “Nurse Educators cannot provide medical advice or in-office medication administration training.” 

Support Path Program (Texas’ “Support Services Program”)

Gilead’s Support Path Program appears to be what Texas calls the “Support Services Program.” The Support Path website says the program “offers information and resources to help patients … understand coverage and financial options for prescribed Gilead and Asegua treatments.”

A Support Path patient brochure describes reimbursement and administrative help, which is likely what the state meant by services “prescribers are duty-bound to perform.” Support Path works with the patient and the provider to research coverage and pass coverage information to both. It also gives the provider information on prior authorization requirements and, on request, follows up with insurers on the status of prior authorizations. For denied claims, a program specialist can identify the reason for the denial, contact the insurer about the appeal process, and give that information to the patient and provider. The health care provider brochure adds that Support Path verifies insurance benefits and in-network pharmacy restrictions. It also offers providers a portal for submitting electronic prior authorizations directly to the payer. 

How the Gilead and AstraZeneca Programs Compare

The two settlements arise from the same enforcement theory, but the conduct alleged, and the details supporting it, are not identical.

Similarities

Same statutes, same payer, same enforcement model. Both cases were brought under the THFPA and TAKS, were tied to prescriptions reimbursed by Texas Medicaid, and originated with qui tam relators. Both companies denied the allegations, and neither settlement is an admission of liability.

Free nursing as in-kind remuneration. In both cases, Texas treated free nursing services and education provided to prescribers and patients as a thing of value that could induce prescriptions.

Reimbursement support as assumed administrative work. In both cases, Texas alleged that the manufacturer took on reimbursement and administrative tasks that prescribers and their staff would otherwise have performed, and the activities at issue overlap substantially. AstraZeneca allegedly provided benefits verification, coverage determination, prior authorization, coding, and appeals support. Gilead’s Support Path materials similarly describe benefits verification, prior authorization information, and an electronic prior authorization portal. Both programs also involved manufacturer personnel contacting payers directly: AstraZeneca’s reimbursement specialists allegedly called patients’ prescription drug plans on their behalf and, according to the complaint, were “trained to misrepresent themselves as the patient’s ‘appointed representative’ or as ‘calling from the doctor’s office,’” while Gilead’s Support Path, on request, allegedly followed up with insurers on the status of prior authorizations. 

Differences

No white coat marketing allegation against Gilead. Texas alleged three schemes against AstraZeneca, including white coat marketing in which third-party vendors allegedly deployed nurses posing as “nurse educators” to recommend AstraZeneca drugs under the guise of disease education. The complaint’s intent allegations centered on this scheme: after sales representatives allegedly struggled to gain access to prescribers following Brilinta’s 2012 launch, AstraZeneca allegedly recruited nurses from the very facilities it sought to access, believing prescribers would view them as more credible than sales representatives, and then gave them sales training and bonuses tied to new prescriptions. In contrast, the Gilead settlement covers only two programs, the “Free Nurse Program” and the “Support Services Program,” and does not allege that Gilead’s Nurse Educators functioned as sales representatives. Because the Gilead complaint remains under seal, the intent allegations against Gilead are not publicly known.

Scope of the nursing services. AstraZeneca’s nurses allegedly improved practice efficiency, provided disease care training and patient education, and answered patient questions on call. By contrast, Gilead’s public materials describe Nurse Educators focused on medication administration and injection training, state that they “cannot provide medical advice or in-office medication administration training,” and direct patients back to their provider with medication questions. These guardrails did not prevent Texas from alleging that the program was in-kind remuneration, but they describe a narrower service than the one alleged against AstraZeneca. As the complaint remains under seal, it is unclear what aspects of the Gilead “Free Nurse Program” that Texas found implicated the THFPA and TAKS. 

Practical Compliance Takeaways

When implementing patient support programs, manufacturers should consider the following.

  • Non-cash services can be remuneration. Texas’ theory did not depend on cash payments to prescribers. It treated free nursing, patient education, reimbursement help, and administrative support as things of value that could induce prescriptions billed to Medicaid. Compliance reviews should evaluate the value of each service provided and ask whether a prescriber or patient might see it as valuable enough to affect prescribing decisions.
  • Ask who would otherwise do the work. Texas framed the Support Services Program as Gilead taking on reimbursement and administrative tasks that prescribers are “duty-bound to perform” for their patients. When reviewing patient-support programs, it is important to consider both the benefit to patients and whether a service relieves prescribers or their staff of costs or work that would otherwise fall on the practice. “Expense relief” is remuneration that implicates both federal and state fraud and abuse laws.
  • Disclaimers help but are not a safe harbor. Gilead’s Nurse Educator materials limited the program’s scope and disclaimed medical advice, yet Texas still alleged the program was in-kind remuneration. Guardrails should be paired with effective auditing and monitoring of what services are actually being provided and to whom.
  • Distinguish education from sales. Confirm that nurses deployed under “educator” or “patient support” titles are not functioning as sales agents or replacing staff prescribers would otherwise employ. Potential red flags include sales training, compensation tied to prescription metrics, use of sales-tracking tools, and sales call targets.
  • State exposure is separate from federal exposure. Texas brought its claims under state law (the THFPA and TAKS), tied them to prescriptions reimbursed by Texas Medicaid, and litigated alongside a qui tam relator. Federal anti-kickback compliance alone may not address state risk. Any compliance review should account for state Medicaid fraud and anti-kickback statutes, particularly in states with active enforcement programs.

The Gilead settlement confirms that the AstraZeneca resolution was not an outlier. Texas is pursuing free nurse and reimbursement support programs as “expense relief” under state law, with or without allegations of white coat marketing or misrepresentation, and the dollar amounts at stake are substantial. Manufacturers should proactively audit their nurse support, reimbursement assistance, and other patient support programs to mitigate state and federal enforcement exposure.

Additional research and writing from Jacquelyn Ellis, a law clerk in ArentFox Schiff’s Washington, DC, office.

Contacts

Continue Reading